Johnson & Johnson (NYSE: JNJ) released its fourth-quarter 2016 financials and the numbers show that the launch of a Remicade biosimilar by Pfizer, Inc. (NYSE: PFE) could pose a big threat to the company's growth in 2017.
A massive market
The market for autoimmune disease drugs like Remicade is huge. Every year, billions of dollars are spent on these drugs, which can cost thousands of dollars per dose.
Remicade is one of the oldest biologics used to treat autoimmune disease, including rheumatoid arthritis, and it's a complex biologic that can't be copied identically. However, patent expiration has led to the launch of biosimilars that deliver similar safety and efficacy.
These biosimilars are already available in abroad markets, including Europe, but they're only now launching in the United States. In November, Pfizer became the first company to launch a Remicade biosimilar in the U.S. when it rolled out Inflectra.
Although Inflectra has only been on the market for weeks, not months, Johnson & Johnson's fourth-quarter financials suggest Remicade's best days are behind it.
In the fourth quarter, Remicade's U.S. sales slipped 1.7% to $1.17 billion. That's a big swing from its third-quarter performance, when Remicade's U.S. sales climbed 9.4% year over year to $1.22 billion. It also suggests tough sledding may be ahead for the company's sales in 2017, given that U.S. Remicade sales totaled $4.84 billion in 2016, up 8.7% from 2015.
What's on deck
Pfizer launched Inflectra with a price tag that's only about 15% less than Remicade, which can cost between $1,300 and $2,500 per dose.
While that's not as big of a discount to the brand name price as typical generic small molecule drugs tend to launch with, it could still be enough to convince payers and doctors to prescribe it to newly diagnosed patients and cost-conscious patients. If so, then Inflectra could carve meaningful market share away from Remicade.
Abroad, where Remicade is marketed by Merck & Co. (NYSE: MRK) , biosimilars are already taking a toll on Remicade, and the experience in those markets offers insight into how the U.S. market could play this year.
Merck & Co. hasn't disclosed its fourth-quarter figures yet, but Remicade sales in the third quarter fell 30% to $311 million versus the third quarter of 2015. When Merck reported those figures, management cited biosimilars as the reason behind Remicade's revenue drop.
Protecting its moat
Johnson & Johnson will likely compete on price with Inflectra by offering greater discounts to payers. That could help it maintain market share against Inflectra, but it will cause headwinds to Remicade's sales and the drug's contribution to Johnson & Johnson's bottom line.
The company hopes to make-up some of the negative drag on its financials caused by biosimilars by expanding the use of other autoimmune disease drugs in its line-up, including Stelara. Stelara is approved for use in psoriasis, and in September, the FDA expanded the drug's label to include its use in Crohn's disease. Johnson & Johnson thinks that could add $500 million in annual sales, or more.
Johnson & Johnson is also working on next-generation drugs that could help sure-up the company's market share in rheumatoid arthritis. Recently, Johnson & Johnson and co-developer GlaxoSmithKline filed for FDA approval of sirukumab, a rheumatoid arthritis drug that industry analysts think could have peak sales potential of $1 billion, or more.
Although Johnson & Johnson's efforts may help it absorb Remicade weakness, Remicade's the company's best selling drug, and that means that it could pose the biggest risk to sales in 2017.
10 stocks we like better than Johnson and Johnson
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Johnson and Johnson wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of January 4, 2017
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.